SCHEMBL2457397

SCHEMBL2457397

Cc1ccc(C(Cl)c2ccc(C)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 7/20 0.50
TDP1 Q9NUW8 1/20 0.50
CHRNA7 P36544 1/20 0.48
ALDH1A1 P00352 4/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
LMNA P02545 4/20 0.38
TP53 P04637 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
NLRP1 Q9C000 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP19A1 P11511 1/20 0.37
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10799692 0.89 TSHR (0.48) ACHETDP1CHRNA7ALDH1A1LMNA
SCHEMBL11201293 0.87 ACHE (0.62) ACHETDP1CHRNA7ALDH1A1LMNA
SCHEMBL9161623 0.82 ALDH1A1 (0.67) ACHEALDH1A1CA2CA9MAPT
SCHEMBL330031 0.81 ACHE (0.50) ACHETDP1CHRNA7ALDH1A1CA1
P-Xylene SCHEMBL17784277 0.79 ACHE (0.67) ACHETDP1CHRNA7ALDH1A1CA1
SCHEMBL897929 0.79 ACHE (0.47) ACHETDP1CHRNA7ALDH1A1CA1
SCHEMBL24047104 0.77 TDP1 (0.59) ACHETDP1CHRNA7ALDH1A1CA1
SCHEMBL6403156 0.77 ACHE (0.44) ACHETDP1CHRNA7ALDH1A1CA1
SCHEMBL721504 0.77 ACHE (0.44) ACHETDP1CHRNA7ALDH1A1CA2
SCHEMBL9017732 0.77 ACHE (0.44) ACHETDP1CHRNA7ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476445-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2013-07-02 US disclosed
US-20110295014-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2011-12-01 US disclosed
US-8022220-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2011-09-20 US disclosed
US-20100137605-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
US-7678915-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2010-03-16 US disclosed
US-20100010227-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2010-01-14 US disclosed
US-7560561-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2009-07-14 US disclosed
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
US-20070010677-A1 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2007-01-11 US disclosed
EP-0877733-B1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES AMR TECHNOLOGY INC (US) 2006-08-09 EP disclosed
EP-0877733-A4 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RES INC (US) 1999-03-31 EP disclosed
EP-0877733-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1998-11-18 EP disclosed
EP-0868182-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1998-10-07 EP disclosed
WO-1997023213-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1997-07-03 WO disclosed
WO-1997022344-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1997-06-26 WO disclosed
WO-1997009983-A1 PIPERIDINE DERIVATIVES AND PROCESSES FOR THEIR PRODUCTION ALBANY MOLECULAR RESEARCH, INC. (US) 1997-03-20 WO disclosed
US-4603145-A Antiatherosclerotic diphenyl alkanamides AMERICAN CYANAMID COMPANY (US) 1986-07-29 US disclosed
US-4536346-A TREATMENT OF ATHEROSCLEROSIS AMERICAN CYANAMID COMPANY (US) 1985-08-20 US disclosed
EP-0124791-A1 Aralkanamidophenyl compounds AMERICAN CYANAMID COMPANY (US) 1984-11-14 EP disclosed
US-4118561-A ANTIBACTERIAL, SYNERGISTIC, ANTI-CANCER ACTIVITY, ANTI-FOLIC ACID ACTIVITY AMERICAN HOME PRODUCTS CORPORATION (US) 1978-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295014-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES OR10J3, NR1H2, NR1H3 ACHE 4353/4885TDP1 4680/4885CHRNA7 205/4885
US-20100137605-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES HPD, PTMA, HAAO ACHE 261/4885TDP1 1905/4885CHRNA7 1654/4885
US-20100010227-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES DDC, HPD, ALDH7A1 ACHE 195/4885TDP1 2061/4885CHRNA7 1513/4885
US-20070010677-A1 Process for production of piperidine derivatives NR4A1, NR5A2, NR4A2 ACHE 3980/4885TDP1 4572/4885CHRNA7 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.